SkyePharma/Sanofi UroXatral "approvable"

Sanofi-Synthelabo and SkyePharma expect to launch UroXatral (once-daily alfuzosin) in 2002, Sanofi says following Oct. 5 "approvable" letter from FDA. European version of benign prostatic hyperplasia treatment was approved in January as Xatral OD